- AI Trailblazers - We moved to MailChimp
- Posts
- How AI is revolutionizing drug development
How AI is revolutionizing drug development
Plus: AI-powered newsrooms face global skepticism, report finds
Today's edition is a quick 3-minute read!
Here are the top 3 stories in AI…
Presented by BrainStation
Unlock the potential of generative AI with our hands-on, expert-led course starting on June 25th. Learn from industry leaders and gain essential skills in AI foundations, generative AI, and business applications. Dive into real-world case studies and practical exercises to master AI tools like ChatGPT.
Ready to elevate your career?
How AI is revolutionizing drug development
In high-tech labs like Terray Therapeutics in Monrovia, California, robots and scientists generate massive data to train AI algorithms, revolutionizing drug discovery. These AI-powered labs are part of a new wave aiming to produce more effective drugs faster by leveraging artificial intelligence.
AI’s role in drug discovery: AI tools at Terray analyze vast molecular data to suggest potential drug candidates, shifting drug discovery from a slow manual process to an automated, precise one. These AI-generated drugs still undergo rigorous lab and clinical testing to ensure safety and efficacy.
Cutting-edge labs and data: Terray's lab, a data factory, generates 50 terabytes daily, fueling AI models that design drug molecules digitally. These designs are tested in the lab, with results refining future iterations, significantly speeding up the development cycle.
The promise and challenges of AI in pharma: AI aims to transform the pharmaceutical industry by reducing drug development time and cost. Traditionally, developing a drug takes 10 to 15 years and costs around $1 billion. AI seeks to improve these odds by accelerating preclinical stages and reducing high failure rates.
The industry's response: Major pharmaceutical companies partner with AI-driven startups to leverage innovative capabilities. Companies like Terray, Recursion Pharmaceuticals, Schrödinger, and Isomorphic Labs lead this revolution, allowing pharma giants to tap into new technologies without significant upfront investment.
The path forward: Despite AI’s potential, drug development remains complex. Terray focuses on drugs for inflammatory diseases, aiming for clinical trials by early 2026. AI's ultimate success will be measured by improved clinical success rates and better drugs for human health.
AI is set to transform drug discovery and development, promising faster, more efficient, and effective processes. This AI-driven revolution could usher in a new era in medicine, with improved outcomes for patients worldwide.
India pulls in tech giants for its AI ambitions
Microsoft and Amazon invest big in India's AI future…
India is emerging as a key player in the AI landscape, attracting massive investments from tech giants like Microsoft and Amazon. These companies are pouring billions into expanding computing infrastructure, aiming to dominate the AI industry.
Major investments:
Microsoft: Committed $3.7 billion to Telangana, acquiring land for data centers with 660 megawatts of IT capacity.
Amazon: Plans to invest $12.7 billion in cloud infrastructure in India by 2030.
“India today is one of the most exciting markets in the world for tech,” said Puneet Chandok, Microsoft’s president for India and South Asia.
AI race intensifies: Tech giants are boosting cloud computing to secure their place in generative AI. Investments from Microsoft, Amazon, and Google total over $85 billion globally, with India set to top the Asia Pacific region for data center capacity.
Economic and environmental impact: India offers substantial incentives for tech investments, fostering a growing digital economy. However, the data center boom raises environmental concerns due to high electricity and water usage. Despite this, Microsoft is committed to becoming carbon-negative by 2030, securing clean energy agreements in India.
India's drive to become a global AI hub is attracting significant investments, positioning the country as a crucial player in the AI industry while balancing economic growth with environmental sustainability.
AI-powered newsrooms face global skepticism
Rising concerns: Global audiences are wary of AI-generated news, with the latest Reuters Institute report highlighting significant distrust. Surveys of nearly 100,000 people across 47 countries reveal skepticism, particularly for sensitive topics like politics.
Misinformation fears: In the U.S., 52% of respondents are uncomfortable with AI-produced news; in the UK, it's 63%. Concerns about false news online have increased, with 59% of respondents worried about misinformation.
Financial struggles: Despite a pandemic boost, only 17% of respondents across 20 countries pay for online news, a figure unchanged for three years. In the U.S., nearly half of subscribers pay discounted rates due to promotions.
Influencers on the rise: Influencers are shaping news consumption on platforms like TikTok. A survey of over 5,600 TikTok users found 57% primarily follow individual personalities for news, overshadowing traditional journalists.
Adapting to change: Newsrooms must build direct relationships with audiences and leverage social media to engage younger viewers. The report suggests mainstream media needs to adapt to the influence of alternative news sources and personalities.
Key takeaways:
Global skepticism: Significant distrust of AI-generated news, especially on sensitive topics.
Misinformation concerns: Growing fears of false news content.
Monetization challenges: Stagnant growth in paid news subscriptions.
Influencer dominance: Rising influence of news personalities on social media.
Strategic adaptation: Need for newsrooms to engage directly with audiences and use social media effectively.